-->

Ramm Pharma Corp Stock Net Income

Fundamental analysis of RAMM Pharma allows traders to better anticipate movements in RAMM Pharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RAMM Pharma Corp Company Net Income Analysis

RAMM Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current RAMM Pharma Net Income

    
  (7.11 M)  
Most of RAMM Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAMM Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, RAMM Pharma Corp reported net income of (7.11 Million). This is 102.08% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 101.24% higher than that of the company.

RAMM Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAMM Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RAMM Pharma could also be used in its relative valuation, which is a method of valuing RAMM Pharma by comparing valuation metrics of similar companies.
RAMM Pharma is currently under evaluation in net income category among its peers.

RAMM Fundamentals

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in RAMM Pink Sheet

If you are still planning to invest in RAMM Pharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RAMM Pharma's history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Stocks Directory
Find actively traded stocks across global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges